Kho Min Chul, Park Ji Hun, Han Byung Hyuk, Tan Rui, Yoon Jung Joo, Kim Hye Yoom, Ahn You Mee, Lee Yun Jung, Kang Dae Gill, Lee Ho Sub
Hanbang Body-fluid Research Center, Wonkwang University, 460 Iksandae-ro, Iksan, Jeonbuk 54538, Korea.
College of Oriental Medicine and Professional Graduate School of Oriental Medicine, Wonkwang University, 460 Iksandae-ro, Iksan, Jeonbuk 54538, Korea.
Nutrients. 2017 Apr 14;9(4):386. doi: 10.3390/nu9040386.
Nephrotic syndrome, a kidney disease with a variety of causes, is mainly characterized by heavy proteinuria, hypoproteinemia, and ascites. This study was designed to evaluate the underlying mechanism of action of L. (PAL) in treating nephrotic syndrome induced by puromycin aminonucleoside.
PAL has been used in Asia as a traditional medicine and dietary health supplement. Sprague-Dawley (SD) rats were intravenously injected with puromycin aminonucleoside (75 mg/kg/day), then treated with either Losartan (30 mg/kg/day) or PAL (200 mg/kg/day) by oral gavage for seven days.
PAL significantly decreased ascites, proteinuria level, and plasma lipid parameters. In addition, treatment with PAL attenuated histological damage and hypoalbuminemia. Treatment with PAL also restored podocin expression and reduced inflammation markers such as intracellular adhesion molecules (ICAM-1), monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor alpha (TNF-α) and high-mobility group box-1 (HMGB1). Lower expression levels of the apoptosis markers Bax, caspase-3 and capase-9 were documented in SD rats receiving PAL. PAL also significantly decreased the phosphorylation levels of MAPKs such as ERK, JNK and p38.
As a multifunctional agent, PAL has a renoprotective effect in nephrotic syndrome rat models. The anti-inflammatory and anti-apoptotic properties, along with reductions in hyperlipidemia and ascites, represent important therapeutic effects. These results indicate that is likely to be a promising agent in the treatment of nephrotic syndrome.
肾病综合征是一种病因多样的肾脏疾病，主要特征为大量蛋白尿、低蛋白血症和腹水。本研究旨在评估紫锥菊提取物（PAL）治疗嘌呤霉素氨基核苷诱导的肾病综合征的潜在作用机制。
PAL在亚洲已作为传统药物和膳食健康补充剂使用。将嘌呤霉素氨基核苷（75毫克/千克/天）静脉注射到Sprague-Dawley（SD）大鼠体内，然后通过口服灌胃给予氯沙坦（30毫克/千克/天）或PAL（200毫克/千克/天），持续7天。
PAL显著降低了腹水、蛋白尿水平和血浆脂质参数。此外，PAL治疗减轻了组织学损伤和低白蛋白血症。PAL治疗还恢复了足突蛋白的表达，并降低了细胞间黏附分子（ICAM-1）、单核细胞趋化蛋白-1（MCP-1）、肿瘤坏死因子α（TNF-α）和高迁移率族蛋白B1（HMGB1）等炎症标志物。在接受PAL的SD大鼠中，凋亡标志物Bax、半胱天冬酶-3和半胱天冬酶-9的表达水平较低。PAL还显著降低了ERK、JNK和p38等丝裂原活化蛋白激酶的磷酸化水平。
作为一种多功能药物，PAL在肾病综合征大鼠模型中具有肾脏保护作用。抗炎和抗凋亡特性，以及高脂血症和腹水的减轻，代表了重要的治疗效果。这些结果表明，PAL可能是治疗肾病综合征的一种有前景的药物。
